Top

Published in:

01-04-2013 | Original Article

The HLA-Cw*06 allele and −1149 G/T polymorphism of extrapituitary promoter of PRL gene as a possible common genetic predisposing factors to psoriasis vulgaris and psoriatic arthritis in Czech population

Authors: Anna Cibulova, Marta Zajacova, Marketa Fojtikova, Jiri Stolfa, Liliana Sedova, Pavlina Cejkova, Jan Lippert, Petr Arenberger, Marie Cerna

Published in: Rheumatology International | Issue 4/2013

Abstract

Psoriatic arthritis (PsA) affects approximately 30 % of patients suffering from psoriasis vulgaris (PsV), but the risk factors for its development have not been well elucidated yet. The HLA-Cw*06 allele was described as a predisposing factor to PsV. Prolactin is known as an immune response modulator, and its elevated levels present risk for PsV development. It is possible that these factors interact and together emphasize the predisposition to both diseases. We tested on an association of HLA-Cw alleles and functional polymorphism −1149 G/T in PRL gene extrapituitary promoter with PsV and PsA in Czech population. We found a statistically significant association between HLA-Cw*06 allele and PsV (P _corrected = 0.0013) that was most prominent in early onset disease subtype (P _corrected = 0.0013). The association between HLA-Cw*06 and PsA was low (P _corrected = 0.0585) and restricted to PsA patients with early PsV onset (P _corrected = 0.0195). We found no association of −1149 G/T PRL gene polymorphism with either PsV or PsA.

Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Suppl 2):ii14–ii17PubMedCrossRef

Alenius GM, Jidell E, Nordmark L, Rantapää Dahlqvist S (2002) Disease manifestations and HLA antigens in psoriatic arthritis in northern Sweden. Clin Rheumatol 21:357–362PubMedCrossRef

Elkayam O, Ophir J, Yaron M, Caspi D (2000) Psoriatic arthritis: interrelationships between skin and joint manifestations related to onset, course and distribution. Clin Rheumatol 19:301–305PubMedCrossRef

Sibilia J (2006) Psoriasis: skin and joints, same fight? J Eur Acad Dermatol Venereol 20(Suppl 2):56–72CrossRef

Gonzalez S, Martinez-Borra J, Torre-Alonso JC, Gonzalez-Roces S, Sanchez del Río J, Rodriguez Pérez A, Brautbar C, López-Larrea C (1999) The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum 42:1010–1016PubMedCrossRef

Gladman DD, Farewell VT, Wong K, Husted J (1998) Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41:1103–1110PubMedCrossRef

Gudjónsson JE, Kárason A, Antonsdóttir AA, Rúnarsdóttir EH, Gulcher JR, Stefánsson K, Valdimarsson H (2002) HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. J Invest Dermatol 118:362–365PubMedCrossRef

Henseler T, Christophers E (1985) Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13:450–456PubMedCrossRef

Swanbeck G, Inerot A, Martinsson T, Wahlström J, Enerbäck C, Enlund F, Yhr M (1995) Age at onset and different types of psoriasis. Br J Dermatol 133:768–773PubMedCrossRef

10.

Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, Jenisch S, Weichenthal M, Abecasis GR, Lim HW, Christophers E, Voorhees JJ, Elder JT (2006) Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 78:827–851PubMedCrossRef

11.

Trembath RC, Clough RL, Rosbotham JL, Jones AB, Camp RD, Frodsham A, Browne J, Barber R, Terwilliger J, Lathrop GM, Barker JN (1997) Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 6:813–820PubMedCrossRef

12.

Martin MP, Nelson G, Lee JH, Pellett F, Gao X, Wade J, Wilson MJ, Trowsdale J, Gladman D, Carrington M (2002) Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 169:2818–2822PubMed

13.

Valdimarsson H (2007) The genetic basis of psoriasis. Clin Dermatol 25:563–567PubMedCrossRef

14.

Nair RP, Stuart P, Henseler T, Jenisch S, Chia NV, Westphal E, Schork NJ, Kim J, Lim HW, Christophers E, Voorhees JJ, Elder JT (2000) Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet 66:1833–1844PubMedCrossRef

15.

Karason A, Gudjonsson JE, Upmanyu R, Antonsdottir AA, Hauksson VB, Runasdottir EH, Jonsson HH, Gudbjartsson DF, Frigge ML, Kong A, Stefansson K, Valdimarsson H, Gulcher JR (2003) A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. Am J Hum Genet 72:125–131PubMedCrossRef

16.

Grubić Z, Perić P, Eeèuk-Jelicić E, Zunec R, Stingl K, Curković B, Kerhin-Brkljacić V (2004) The MICA-A4 triplet repeats polymorphism in the transmembrane region confers additional risk for development of psoriatic arthritis in the Croatian population. Eur J Immunogenet 31:93–98PubMedCrossRef

17.

Ho PY, Barton A, Worthington J, Thomson W, Silman AJ, Bruce IN (2007) HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis. Ann Rheum Dis 66:807–811PubMedCrossRef

18.

Fojtikova M, Stolfa J, Novota P, Cejkova P, Dostal C, Cerna M (2009) HLA-Cw*06 class I region rather than MICA is associated with psoriatic arthritis in Czech population. Rheumatol Int 29:1293–1299PubMedCrossRef

19.

Matalka KZ (2003) Prolactin enhances production of interferon-gamma, interleukin-12, and interleukin-10, but not of tumor necrosis factor-alpha, in a stimulus-specific manner. Cytokine 21:187–194PubMedCrossRef

20.

Kanda N, Watanabe S (2007) Prolactin enhances interferon-gamma-induced production of CXC ligand 9 (CXCL9), CXCL10, and CXCL11 in human keratinocytes. Endocrinology 148:2317–2325PubMedCrossRef

21.

McMurray RW (2001) Bromocriptine in rheumatic and autoimmune diseases. Semin Arthritis Rheum 31:21–32PubMedCrossRef

22.

Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW (1996) Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 17:639–669PubMed

23.

De Bellis A, Bizzarro A, Pivonello R, Lombardi G, Bellastella A (2005) Prolactin and autoimmunity. Pituitary 8:25–30PubMedCrossRef

24.

Moszkorzova L, Lacinova Z, Marek J, Musilova L, Dohnalova A, Dostal C (2002) Hyperprolactinemia in patients with systemic lupus erythematosus. Clin Exp Rheumatol 20:807–812PubMed

25.

Leanos-Miranda A, Cardenas-Mondragon G (2006) Serum free prolactin concentrations in patients with systemic lupus erythematosus are associated with lupus activity. Rheumatology 45:97–101PubMedCrossRef

26.

Fojtíková M, Tomasová Studýnková J, Filková M, Lacinová Z, Gatterová J, Pavelka K, Vencovský J, Senolt L (2010) Elevated prolactin levels in patients with rheumatoid arthritis: association with disease activity and structural damage. Clin Exp Rheumatol 28:849–854PubMed

27.

Dilme-Carreras E, Martin-Ezquerra G, Sanchez-Regana M, Umbert-Millet P (2011) Serum prolactin levels in psoriasis and correlation with cutaneous disease activity. Clin Exp Dermatol 36:29–32PubMedCrossRef

28.

El-Khateeb EA, Zuel-Fakkar NM, Eid SM, Abdul-Wahab SE (2011) Prolactin level is significantly elevated in lesional skin of patients with psoriasis. Int J Dermatol 50:693–696PubMedCrossRef

29.

Malligarjunan H, Gnanaraj P, Subramanian S, Elango T, Dayalan H (2011) Clinical efficacy of propylthiouracil and its influence on prolactin in psoriatic patients. Clin Biochem 44:1209–1213PubMedCrossRef

30.

Berwaer M, Martial JA, Davis JR (1994) Characterization of an upstream promoter directing extrapituitary expression of the human prolactin gene. Mol Endocrinol 8:635–642PubMedCrossRef

31.

Reem GH, Ray DW, Davis JRE (1999) The human prolactin gene upstream promoter is regulated in lymphoid cells by activators of T-cells and by cAMP. J Mol Endocrinol 22:285–292PubMedCrossRef

32.

Stevens A, Ray D, Alansari A, Hajeer A, Thomson W, Donn R, Ollier WE, Worthington J, Davis JR (2001) Characterization of a prolactin gene polymorphism and its associations with systemic lupus erythematosus. Arthritis Rheum 44:2358–2366PubMedCrossRef

33.

Stevens A, Ray DW, Worthington J, Davis JR (2001) Polymorphisms of the human prolactin gene—implications for production of lymphocyte prolactin and systemic lupus erythematosus. Lupus 10:676–683PubMedCrossRef

34.

Lee YC, Raychaudhuri S, Cui J, De Vivo I, Ding B, Alfredsson L, Padyukov L, Costenbader KH, Seielstad M, Graham RR, Klareskog L, Gregersen PK, Plenge RM, Karlson EW (2009) The PRL -1149 G/T polymorphism and rheumatoid arthritis susceptibility. Arthritis Rheum 60:1250–1254PubMedCrossRef

35.

Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55–78PubMedCrossRef

36.

Mallon E, Bunce M, Wojnarowska F, Welsh K (1997) HLA-Cw*0602 is a susceptibility factor in type I psoriasis, and evidence Ala-73 is increased in male type I psoriatics. J Invest Dermatol 109:183–186PubMedCrossRef

37.

Gudjonsson JE, Karason A, Runarsdottir EH, Antonsdottir AA, Hauksson VB, Jónsson HH, Gulcher J, Stefansson K, Valdimarsson H (2006) Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients–an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 126:740–745PubMedCrossRef

38.

Sczcerkowska Dobosz A, Rebala K, Szczerkowska Z, Nedoszytko B (2005) HLA-C locus alleles distribution in patients from northern Poland with psoriatic arthritis: preliminary report. Int J Immunogenet 32:389–391CrossRef

39.

Gladman DD, Cheung C, Ng CM, Wade JA (1999) HLA-C locus alleles in patients with psoriatic arthritis (PsA). Hum Immunol 60:259–261PubMedCrossRef

40.

Ho PY, Barton A, Worthington J, Plant D, Griffiths CE, Young HS, Bradburn P, Thomson W, Silman AJ, Bruce IN (2008) Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriasis arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann Rheum Dis 67:677–682PubMedCrossRef

41.

Queiro R, Torre JC, González S, López-Larrea C, Tinturé T, López-Lagunas I (2003) HLA antigens may influence the age of onset of psoriasis and psoriatic arthritis. J Rheumatol 30:505–507PubMed

42.

Queiro R, Gonzales S, Lopez-Larrea C, Alperi M, Sarasqueta C, Riestra JL, Ballina J (2006) HLA-C locus alleles may modulate the clinical expression of psoriatic arthritis. Arthritis Res Ther 8:R185PubMedCrossRef

43.

Gellersen B, Kempf R, Telgmann R, DiMattia GE (1994) Nonpituitary human prolactin gene transcription is independent of Pit-1 and differentially controlled in lymphocytes and in endometrial stroma. Mol Endocrinol 8:356–357PubMedCrossRef

Title: The HLA-Cw*06 allele and −1149 G/T polymorphism of extrapituitary promoter of PRL gene as a possible common genetic predisposing factors to psoriasis vulgaris and psoriatic arthritis in Czech population
Authors: Anna Cibulova
Marta Zajacova
Marketa Fojtikova
Jiri Stolfa
Liliana Sedova
Pavlina Cejkova
Jan Lippert
Petr Arenberger
Marie Cerna
Publication date: 01-04-2013
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 4/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-012-2472-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

A profile of gout patients in Sarawak

HLA-DRβ1*04 typing by simple in-house PCR-SSP technique for rheumatoid arthritis patients

Association of von Willebrand factor and fibrinogen plasma levels with primary Raynaud’s phenomenon in male and female patients

Demographic and clinical features of gout patients in Turkey: a multicenter study

Brucellar spondylodiscitis: comparison of patients with and without abscesses

Stressors and rheumatoid arthritis: changes in stressors with advances in therapeutic agents

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials